Lord, Abbett & Co. LLC Exelixis, Inc. Transaction History

Lord, Abbett & Co. LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$20.53 - $25.22 $8.44 Million - $10.4 Million	-411,200 Closed	0 $0
Q4 2020 Feb 09, 2021	SELL	$18.39 - $24.8 $6.67 Million - $8.99 Million	-362,515 Reduced 46.85%	411,200 $8.25 Million
Q3 2020 Nov 12, 2020	BUY	$20.67 - $26.94 $16 Million - $20.8 Million	773,715 New	773,715 $18.9 Million
Q2 2019 Aug 14, 2019	SELL	$18.93 - $24.75 $19.1 Million - $24.9 Million	-1,007,275 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $19.7 Million - $24.9 Million	1,007,275 New	1,007,275 $24 Million
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $18.1 Million - $26.1 Million	-818,178 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$24.23 - $30.93 $72,762 - $92,882	3,003 Added 0.37%	818,178 $24.9 Million
Q3 2017 Nov 14, 2017	SELL	$23.35 - $29.24 $48.8 Million - $61.2 Million	-2,091,545 Reduced 71.96%	815,175 $19.8 Million
Q2 2017 Aug 14, 2017	BUY	N/A	2,906,720	2,906,720 $71.6 Million

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.